NEW YORK (AP) -- Shares of biotechnology company GTX Inc. stumbled Monday on concerns on the risks involved with a late-stage study of the company's prostate cancer drug Acapodene. The drug is aimed at treating bone loss associated with androgen deprivation therapy in prostate cancer patients. The therapy is used to reduce levels of androgens (ADT therapy), such as testosterone, in the body in order to shrink prostate cancer. Another study is focusing on prostate cancer prevention.
